Adding production suites to its 35,000 sq ft cell culture site in Minneapolis gives Biovest capacity to manufacture its late-stage, autologous, active immunotherapy for treating non-Hodgkin’s lymphoma.
“This is a key milestone as we are initiating the commissioning and validation processes with the facility currently undergoing comprehensive testing and review”, said Samuel Duffey, president of Biovest.
Production of the vaccine, called BiovaxID, is due to begin at the new suites this summer. Biovest is preparing for meetings with US and international regulators to discuss seeking approvals for BiovaxID.